
Please try another search
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for the treatment of influenza viruses. The company also develops dengue vaccines, which has completed Phase II clinical trial to treat dengue; anti respiratory syncytial virus (RSV), which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19. Medigen Vaccine Biologics Corporation was incorporated in 2012 and is headquartered in Zhubei City, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.
Name | Age | Since | Title |
---|---|---|---|
Chia-Hsiu Lin | - | 2024 | Director |
Tsan-Chien Chen | - | 2012 | Director |
Ming Cheng Chang | - | 2015 | Chairman |
Chin-Yen Chen | - | 2024 | Representative Director |
Yao-Chi Li | - | 2018 | Independent Director |
Peng-Fei Su | - | 2024 | Independent Director |
Ming-Yi Wu | - | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review